Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Metrics to compare | IMNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMNMPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.7x | −1.9x | −0.5x | |
PEG Ratio | −0.07 | −0.11 | 0.00 | |
Price/Book | 3.1x | 2.2x | 2.6x | |
Price / LTM Sales | 87.7x | 9.7x | 3.2x | |
Upside (Analyst Target) | 118.0% | 153.2% | 42.0% | |
Fair Value Upside | Unlock | 27.9% | 6.6% | Unlock |